The first part of this study is to optimize diagnostic criteria for BMS, i.e. not a clinical trial, and will not be covered in this application. The second part will compare topical treatment with clonazepam, capsaicin and placebo in a n-of-1 study design regarding effects of pain, pain-related disability, somatosensory changes in the trigeminal nerve and patient experience in patients with primary BMS or other oral mucosal pain. The patients will be treated for two weeks with each drug, with a one-week wash-out period in between. After the last washed-out period, the patients will be able to chose the treatment that they prefer the most and continue with that treatment during 6 months.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Pain intensity
Timeframe: Point measurement, will be assessed immediately before start of treatment
Pain intensity
Timeframe: Point measurement, will be assessed 10 days after treatment start for each treatment period.
Pain intensity
Timeframe: Point measurement, will be assessed the day after each treatment period is finished (22 days after start of each treatment)
Patient satisfaction
Timeframe: Point measurement, will be assessed immediately before start of treatment
Patient satisfaction
Timeframe: Point measurement, will be assessed 10 days after treatment start for each treatment period.
Patient satisfaction
Timeframe: Point measurement, will be assessed the day after each treatment period is finished (22 days after start of each treatment)